Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 302

1.
2.

Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.

Kato Y.

Brain Tumor Pathol. 2015 Jan;32(1):3-11. doi: 10.1007/s10014-014-0202-4. Epub 2014 Oct 17. Review.

PMID:
25324168
3.

Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations.

Kaneko MK, Morita S, Tsujimoto Y, Yanagiya R, Nasu K, Sasaki H, Hozumi Y, Goto K, Natsume A, Watanabe M, Kumabe T, Takano S, Kato Y.

Biochem Biophys Res Commun. 2013 Mar 1;432(1):40-5. doi: 10.1016/j.bbrc.2013.01.088. Epub 2013 Jan 31.

PMID:
23376717
4.

Novel monoclonal antibodies GMab-r1 and LMab-1 specifically recognize IDH1-R132G and IDH1-R132L mutations.

Kaneko MK, Tsujimoto Y, Hozumi Y, Goto K, Kato Y.

Monoclon Antib Immunodiagn Immunother. 2013 Jun;32(3):224-8. doi: 10.1089/mab.2013.0006.

PMID:
23750482
5.

Multi-specific monoclonal antibody MsMab-2 recognizes IDH1-R132L and IDH2-R172M mutations.

Ogasawara S, Kaneko MK, Tsujimoto Y, Liu X, Kato Y.

Monoclon Antib Immunodiagn Immunother. 2013 Dec;32(6):377-81. doi: 10.1089/mab.2013.0050.

PMID:
24328739
6.

A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation.

Kato Y, Natsume A, Kaneko MK.

Biochem Biophys Res Commun. 2013 Mar 22;432(4):564-7. doi: 10.1016/j.bbrc.2013.02.049. Epub 2013 Feb 26.

PMID:
23485467
7.

Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.

Liu X, Kato Y, Kaneko MK, Sugawara M, Ogasawara S, Tsujimoto Y, Naganuma Y, Yamakawa M, Tsuchiya T, Takagi M.

Cancer Med. 2013 Dec;2(6):803-14. doi: 10.1002/cam4.149. Epub 2013 Oct 17.

8.

Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation.

Kaneko MK, Tian W, Takano S, Suzuki H, Sawa Y, Hozumi Y, Goto K, Yamazaki K, Kitanaka C, Kato Y.

Biochem Biophys Res Commun. 2011 Mar 25;406(4):608-13. doi: 10.1016/j.bbrc.2011.02.102. Epub 2011 Feb 23.

PMID:
21352804
9.

A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma.

Liu X, Ogasawara S, Kaneko MK, Oki H, Hozumi Y, Goto K, Takagi M, Kato Y.

Biochem Biophys Res Commun. 2015 Apr 17;459(4):636-42. doi: 10.1016/j.bbrc.2015.02.162. Epub 2015 Mar 6.

PMID:
25753205
10.

Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation.

Kato Y, Kaneko MK.

Biochem Biophys Res Commun. 2013 Apr 19;433(4):374-8. doi: 10.1016/j.bbrc.2013.02.106. Epub 2013 Mar 20.

PMID:
23524262
11.

A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas.

Fujii Y, Ogasawara S, Oki H, Liu X, Kaneko MK, Takano S, Kato Y.

Biochem Biophys Res Commun. 2015 Oct 30;466(4):733-9. doi: 10.1016/j.bbrc.2015.09.070. Epub 2015 Sep 14.

PMID:
26381180
12.

A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation.

Kato Y, Jin G, Kuan CT, McLendon RE, Yan H, Bigner DD.

Biochem Biophys Res Commun. 2009 Dec 18;390(3):547-51. doi: 10.1016/j.bbrc.2009.10.001. Epub 2009 Oct 7.

13.

Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.

Kato Kaneko M, Liu X, Oki H, Ogasawara S, Nakamura T, Saidoh N, Tsujimoto Y, Matsuyama Y, Uruno A, Sugawara M, Tsuchiya T, Yamakawa M, Yamamoto M, Takagi M, Kato Y.

Cancer Sci. 2014 Jun;105(6):744-8. doi: 10.1111/cas.12413.

14.

Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.

Chotirat S, Thongnoppakhun W, Promsuwicha O, Boonthimat C, Auewarakul CU.

J Hematol Oncol. 2012 Mar 7;5:5. doi: 10.1186/1756-8722-5-5.

15.

Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.

Agarwal S, Sharma MC, Jha P, Pathak P, Suri V, Sarkar C, Chosdol K, Suri A, Kale SS, Mahapatra AK, Jha P.

Neuro Oncol. 2013 Jun;15(6):718-26. doi: 10.1093/neuonc/not015. Epub 2013 Mar 13.

16.

Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors.

Takano S, Kato Y, Yamamoto T, Kaneko MK, Ishikawa E, Tsujimoto Y, Matsuda M, Nakai K, Yanagiya R, Morita S, Tsuboi K, Matsumura A.

J Neurooncol. 2012 Jul;108(3):361-73. doi: 10.1007/s11060-012-0837-0. Epub 2012 Mar 7.

PMID:
22396072
17.

D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma.

Pusch S, Schweizer L, Beck AC, Lehmler JM, Weissert S, Balss J, Miller AK, von Deimling A.

Acta Neuropathol Commun. 2014 Feb 14;2:19. doi: 10.1186/2051-5960-2-19.

18.

2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.

Jin G, Reitman ZJ, Spasojevic I, Batinic-Haberle I, Yang J, Schmidt-Kittler O, Bigner DD, Yan H.

PLoS One. 2011 Feb 4;6(2):e16812. doi: 10.1371/journal.pone.0016812.

19.

IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.

Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, Pollock R, O'Donnell P, Grigoriadis A, Diss T, Eskandarpour M, Presneau N, Hogendoorn PC, Futreal A, Tirabosco R, Flanagan AM.

J Pathol. 2011 Jul;224(3):334-43. doi: 10.1002/path.2913. Epub 2011 May 19.

PMID:
21598255
20.

IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.

Mellai M, Piazzi A, Caldera V, Monzeglio O, Cassoni P, Valente G, Schiffer D.

J Neurooncol. 2011 Nov;105(2):345-57. doi: 10.1007/s11060-011-0596-3. Epub 2011 Jun 4.

PMID:
21643842
Items per page

Supplemental Content

Write to the Help Desk